;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Absorb: Completed pivotal trial enrollment

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Absorb (bioresorbable vascular scaffold) Business: Cardiovascular Molecular target: Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) Description: Everolimus-…

    Published on 4/21/2014
  • Absorb: Completed pivotal trial enrollment

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Absorb (bioresorbable vascular scaffold) Business: Cardiovascular Molecular target: Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) Description: Everolimus-…

    Published on 4/21/2014
  • Absorb: Completed pivotal trial enrollment

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Absorb (bioresorbable vascular scaffold) Business: Cardiovascular Molecular target: Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) Description: Everolimus-…

    Published on 4/21/2014
  • AEM-28: Phase Ia started

    Capstone Therapeutics Corp. (NASDAQ:CAPS), Tempe, Ariz. LipimetiX LLC, Boston, Mass. Product: AEM-28 Business: Endocrine/Metabolic Molecular target: Low-density lipoprotein receptor-related proteins (LRP); Heparan …

    Published on 4/21/2014
  • AG-348: Phase I started

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Product: AG-348 Business: Endocrine/Metabolic Molecular target: NA Description: Oral small molecule activator of pyruvate kinase R Indication: Treat pyruvate …

    Published on 4/21/2014
  • AKB-6548: Completed Phase IIb enrollment

    Akebia Therapeutics Inc. (NASDAQ:AKBA), Cambridge, Mass. Product: AKB-6548 Business: Hematology Molecular target: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Description: Oral hypoxia-inducible factor …

    Published on 4/21/2014
  • Ampyra dalfampridine: Phase III delayed

    Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Product: Ampyra dalfampridine (Fampyra fampridine - EU) (BIIB041) Business:…

    Published on 4/21/2014
  • Androxal enclomiphene: Completed Phase III enrollment

    Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Androxal enclomiphene Business: Endocrine/Metabolic Molecular target: Androgen receptor; Estrogen receptor Description: Trans-isomer of clomiphene …

    Published on 4/21/2014
  • APR-246: Phase Ib/II started

    Aprea AB, Solna, Sweden Product: APR-246 (PRIMA-1MET) Business: Cancer Molecular target: p53 Description: Small molecule quinuclidinone that promotes correct folding of p53 Indication: Treat relapsed, platinum-sensitive…

    Published on 4/21/2014
  • DCR-MYC: Phase I started

    Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA), Watertown, Mass. Product: DCR-MYC Business: Cancer Molecular target: v-myc myelocytomatosis viral oncogene homolog (MYC) (c-Myc) Description: Dicer substrate short interfering…

    Published on 4/21/2014
  • Gencaro bucindolol: Phase IIb/III started

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Aeolus Pharmaceuticals Inc. (OTCQB:AOLS), Mission Viejo, Calif. Arca biopharma Inc. (NASDAQ:ABIO), Broomfield, Colo. Medtronic Inc. (NYSE:MDT), Minneapolis,…

    Published on 4/21/2014
  • Heplisav: Phase III started

    Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Product: Heplisav (V270) Business: Infectious Molecular target: Toll-like receptor 9 (TLR9) Description: Hepatitis B surface antigen (HBsAg) given with …

    Published on 4/21/2014
  • HuCNS-SC: Completed Phase I/II enrollment

    StemCells Inc. (NASDAQ:STEM), Newark, Calif. Product: HuCNS-SC (human neural stem cells) Business: Neurology Molecular target: Not applicable Description: Purified human neural stem cells Indication: Treat chronic …

    Published on 4/21/2014
  • Livatag doxorubicin Transdrug: Phase III ongoing

    BioAlliance Pharma S.A. (Euronext:BIO), Paris, France Product: Livatag doxorubicin Transdrug (BA-003) Business: Cancer Molecular target: DNA Description: Nanoparticle formulation of doxorubicin Indication: Treat …

    Published on 4/21/2014
  • PAN-90806: Phase I started

    PanOptica Inc., Mount Arlington, N.J. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: PAN-90806 Business: Ophthalmic Molecular target: Vascular endothelial growth factor (VEGF) Description: Small molecule …

    Published on 4/21/2014
  • Selinexor: Phase I started

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 4/21/2014
  • TD-4208: Phase IIb started

    Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. Product: TD-4208 (formerly GSK1160724) Business: Pulmonary Molecular target: Muscarinic receptor Description: Inhaled long-acting muscarinic antagonist (LAMA) …

    Published on 4/21/2014
  • Teriparatide nasal spray: Phase I started

    Critical Pharmaceuticals Ltd., Nottingham, U.K. Product: Teriparatide nasal spray (CP046) Business: Musculoskeletal Molecular target: Parathyroid hormone (PTH) receptor Description: Nasal spray formulation of …

    Published on 4/21/2014
  • Toraymyxin polymyxin B immobilized fiber column: Phase III ongoing

    Spectral Diagnostics Inc. (TSX:SDI; OTCQX:DIAGF), Toronto, Ontario Product: Toraymyxin polymyxin B immobilized fiber column Business: Infectious Molecular target: NA Description: Hemoperfusion absorption column made of …

    Published on 4/21/2014
  • Trichuris suis ova: Phase II started

    Coronado Biosciences Inc. (NASDAQ:CNDO), Burlington, Mass. Product: Trichuris suis ova (TSO) (CNDO-201) Business: Neurology Molecular target: NA Description: Ova from the porcine helminth Trichuris suis that acts as a …

    Published on 4/21/2014
  • Veliparib: Phase III started

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Veliparib (ABT-888) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Oral inhibitor of poly(ADP-ribose) polymerase (PARP) Indication: …

    Published on 4/21/2014
  • VTX-2337: Completed Phase II enrollment

    VentiRx Pharmaceuticals Inc., Seattle, Wash. Product: VTX-2337 Business: Cancer Molecular target: Toll-like receptor 8 (TLR8) Description: Small molecule toll-like receptor 8 (TLR8) agonist Indication: Treat recurrent …

    Published on 4/21/2014
  • WX-037: Development discontinued

    UCB Group (Euronext:UCB), Brussels, Belgium Wilex AG (Xetra:WL6), Munich, Germany Product: WX-037 Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) Description: Phosphoinositide 3-kinase (PI3K) …

    Published on 4/21/2014
  • WX-554: Development discontinued

    UCB Group (Euronext:UCB), Brussels, Belgium Wilex AG (Xetra:WL6), Munich, Germany Product: WX-554, MK-554 Business: Cancer Molecular target: MEK Description: Orally available, small molecule MEK inhibitor Indication: …

    Published on 4/21/2014
  • Xarelto rivaroxaban: Phase III started

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Xarelto rivaroxaban (BAY 59-7939) Business: Cardiovascular Molecular target: Factor Xa Description: Direct Factor Xa …

    Published on 4/21/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993